Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)

Last updated: December 8, 2021
Sponsor: Beijing Ditan Hospital
Overall Status: Active - Recruiting

Phase

1

Condition

Liver Disease

Cancer

Liver Disorders

Treatment

N/A

Clinical Study ID

NCT05152498
BeijingDH-YZY
  • Ages 18-75
  • All Genders

Study Summary

The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Meet the criteria of hepatocellular carcinoma
  • Ages Eligible for Study: ≤75 years old;
  • Informed consent from the patient.

Exclusion

Exclusion Criteria:

  • Serious problem of heart, lung, or kidney with severe dysfunction;
  • Pregnant or child breast feeding women;
  • Mental or cognitive disorders;
  • Participating in other drug trials;
  • Who are allergic to the study drug

Study Design

Total Participants: 142
Study Start date:
January 01, 2021
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Zhiyun Yang

    Beijing, Beijing 100015
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.